ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Goldsmith Named CEO of CancerCare

April 11, 2014

Breast Cancer Risk Prediction Improved In Atypia Cases

July 27, 2007

Cold Spring Harbor Joins SWOG, Becoming First Lab To Join Cooperative Group

November 4, 2011

In Brief: san Antonio’s ICRC Gets a New Name, SACI; Blum Is deputy Oncology Director At Kaplan

May 14, 1993

Contracts Cutback Canceled 7 RFPs

August 8, 1980

In Brief: NCAB Dec. Meeting Includes Biologics Symposium; Epidemiology Center Grant Program Disapproved

November 29, 1985